The use of transdermal nicotine in smoking cessation.
The transdermal administration of nicotine by means of a transdermal nicotine system (TNS) affords a novel way of nicotine replacement to alleviate smoking cessation. The plasma levels of nicotine maintained with the TNS are in the range of the footpoint concentrations observed in smokers. The efficacy of the TNS was investigated in two placebo-controlled double-blind smoking cessation programs with minimal contact and minimal psychological support. A total of 311 smokers were treated for 3 months or 9 weeks. The abstinence rates at the end of the treatment and weaning periods were almost doubled in the TNS groups (36% and 39%) as compared to the placebo groups (23% and 20%) with a significant difference for both studies (p less than 0.05). These data suggest that the TNS can also improve the smoking cessation rates under the conditions of general medical advice, making it suitable for use outside of specialized smoking cessation centers.
Müller
P
P
Pharmaceutical Division, CIBA-GEIGY Ltd., Basle, Switzerland.
Abelin
T
T
Ehrsam
R
R
Imhof
P
P
Howald
H
H
Mauli
D
D
D000279:Administration, Cutaneous; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009538:Nicotine / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D012907:Smoking / Q000188:drug therapy*; D013557:Switzerland
D009538:Nicotine